The FDA grants Fast Track designation to sonelokimab for moderate to severe palmoplantar pustulosis, a chronic inflammatory skin disease.

“EFFISAYIL™ 2 is the first and largest multinational randomized clinical trial to evaluate a treatment for the prevention of GPP flares,” said Bruce Strober, MD, PhD, Clinical Professor, Dermatology, ...

Cutaneous manifestations are common among patients with pediatric autoinflammatory bone diseases and may precede bone involvement.

Please provide your email address to receive an email when new articles are posted on . The mean annualized flare rate per patient per year was 0.91, with a mean time of 5.9 months between flares.

Tender, rupturing pustule on the chin A man complained of mild-to-moderate sensitivity in his lower incisor whenever he chewed for the past year. Four months ago, a painful tender swelling developed ...

Scalp rosacea is an uncommon skin condition causing discoloration or redness and pus-filled bumps on the top of the head. It tends to affect males in an atypical pattern. Rosacea is a chronic skin ...

Erosive pustular dermatosis (EPD) is a chronic inflammatory skin disorder predominantly affecting the scalp of older individuals, often in areas of pre-existing actinic damage and androgenetic ...

Imsidolimab is an investigational humanized IgG4 antibody that inhibits the function of the interleukin-36 receptor. Findings from two phase 3 trials showed skin clearance was achieved and maintained ...